Recruiting Macular Degeneration Studies in Modesto
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)...
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan...
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 ...
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 int...
About Macular Degeneration Clinical Trials in Modesto
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.
There are currently 4 macular degeneration clinical trials recruiting participants in Modesto, CALIFORNIA. These studies are seeking a combined 1,085 participants. Research is being sponsored by Kodiak Sciences Inc, Boehringer Ingelheim, EyeBiotech Ltd.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Macular Degeneration Clinical Trials in Modesto — FAQ
Are there macular degeneration clinical trials in Modesto?
Yes, there are 4 macular degeneration clinical trials currently recruiting in Modesto, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Modesto?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Modesto research site will contact you about next steps.
Are clinical trials in Modesto free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Modesto studies also compensate for your time and travel.
What macular degeneration treatments are being tested?
The 4 active trials in Modesto are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.
Data updated March 2, 2026 from ClinicalTrials.gov